Thomas H. Kean
Thomas H. Kean (R-NJ) bought $1K-$15K of $ILMN (Illumina, Inc. - Common Stock (ILMN) [ST]) on Apr 1, 2025, part of 3 transactions in this filing.
HillSignal flagged 2 timing concerns on this filing — trades that line up closely with related legislative or contract activity.
Companies in this filing · 2
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Suspicious Timing Detected
2 flagsThese flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $ILMN | Illumina, Inc. - Common Stock (ILMN) [ST] | $1K-$15K | $78.39 | $127.88 | +63.1% | Apr 1, 2025 |
| BUY | $NVT | nVent Electric plc Ordinary Shares (NVT) [ST] | $1K-$15K | $55.07 | — | — | Mar 7, 2025 |
| BUY | $NVT | nVent Electric plc Ordinary Shares (NVT) [ST] | $1K-$15K | $55.07 | — | — | Apr 1, 2025 |
Connected Legislative Activity
4 signalsThese bills and contracts share tickers or sectors with this filing's trades.
DeOndra Dixon INCLUDE Project Act of 2025
HR3491 (DeOndra Dixon INCLUDE Project Act) authorizes a Down syndrome research program at NIH but appropriates zero funding. With only 5 procedural actions over a year and stalled committee markup, the bill has no near-term market impact. No public companies are directly affected.
Ellie’s Law
Ellie's Law (HR2678) is an early-stage authorization bill directing NINDS to research unruptured intracranial aneurysms. It authorizes zero dollars, has no funding appropriation, and has only been referred to committee. Market impact is negligible in the near term for device and research tool providers like MDT, TMO, ILMN, and DGX, as no actual spending exists and the legislative path is years from completion.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
S. 339 authorizes Medicare coverage for FDA-approved multi-cancer early detection screening tests starting in 2028, creating a new government-reimbursed revenue stream for diagnostic companies. The bill is in early legislative stages (referred to committee since Jan 2025) with 68 cosponsors and an identical House companion that has advanced further. Pure-play liquid biopsy developers and reference laboratories with processing infrastructure are positioned to benefit.
BRAIN Act
The BRAIN Act (HR2767) is an early-stage bill in the 119th Congress that authorizes no funding and has been referred to committee. Near-term market impact is negligible. The bill creates programmatic structures for brain tumor research, biospecimen transparency, and biomarker testing awareness, but actual market effects require future appropriations and bill text clarity. No publicly traded companies face material revenue exposure at this stage.
Other Filings by Thomas H. Kean
Free — no credit card
Get the next Kean trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.